SCHEMBL27084686

SCHEMBL27084686

CC1OC(Oc2cccc3[nH]cc(CCN(C(C)C)C(C)C)c23)C(O)C(O)C1O

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SLC5A2 P31639 18/20 0.53
▸ SLC5A1 P13866 11/20 0.53
▸ HTR6 P50406 2/20 0.45
▸ HTR3E A5X5Y0 1/20 0.45
▸ HTR3B O95264 1/20 0.45
▸ HTR1A P08908 1/20 0.45
▸ HTR1D P28221 1/20 0.45
▸ HTR1B P28222 1/20 0.45
▸ HTR2A P28223 1/20 0.45
▸ HTR2C P28335 1/20 0.45
▸ HTR1E P28566 1/20 0.45
▸ HTR1F P30939 1/20 0.45
▸ HTR7 P34969 1/20 0.45
▸ HTR2B P41595 1/20 0.45
▸ HTR3A P46098 1/20 0.45
▸ HTR5A P47898 1/20 0.45
▸ HTR4 Q13639 1/20 0.45
▸ HTR3D Q70Z44 1/20 0.45
▸ HTR3C Q8WXA8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29112608 0.91 SLC5A2 (0.52) SLC5A2SLC5A1HTR6HTR1AHTR2A
SCHEMBL27084837 0.90 SLC5A2 (0.52) SLC5A2SLC5A1HTR6
SCHEMBL27084684 0.89 SLC5A2 (0.67) SLC5A2SLC5A1
SCHEMBL27084669 0.89 HTR6 (0.58) SLC5A2SLC5A1HTR6HTR1AHTR1D
SCHEMBL27085121 0.87 SLC5A2 (0.55) SLC5A2SLC5A1HTR6HTR1A
SCHEMBL27085009 0.86 SLC5A2 (0.54) SLC5A2SLC5A1HTR6HTR1AHTR2A
SCHEMBL27085022 0.86 SLC5A2 (0.56) SLC5A2SLC5A1HTR6HTR1A
SCHEMBL27085141 0.85 SLC5A2 (0.51) SLC5A2SLC5A1HTR6HTR1AHTR2A
SCHEMBL27085123 0.85 SLC5A2 (0.54) SLC5A2SLC5A1HTR1AHTR2A
SCHEMBL27084990 0.84 HTR6 (0.44) SLC5A2SLC5A1HTR6HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240043382-A1 MODIFIED INDOLE ALKALOIDS FOR THERAPEUTIC USES COMPASS PATHFINDER LIMITED (GB) 2024-02-08 — — US disclosed
CN-117120415-A Modified indole alkaloids for therapeutic use 指南针探路者有限公司 2023-11-24 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240043382-A1 MODIFIED INDOLE ALKALOIDS FOR THERAPEUTIC USES INMT, AANAT, HNMT SLC5A2 3921/4885SLC5A1 3810/4885HTR6 57/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback